Home・Stock List・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Open

SectorHealthcare

35.23 -0.48

Buy Sell

Overview

Share price change

24h

Current

Min

34.6

Max

35.72

Key metrics
By Trading Economics
Income	2.6M -79M
Sales	-60K 15K
EPS	-1.18
Profit margin	-524,566.667
Employees	198
EBITDA	2.7M -78M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+55.51% upside

Dividends
By Acuity
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	208M 2.8B
Previous open	35.71
Previous close	35.23

News Sentiment

By Acuity

50%

138 / 340 Healthcare

Celldex Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

22 Jul 2026, 20:01 UTC

Event

News

Social Media

Celldex Therapeutics is lower after discontinuing barzolvolimab development due to failed trial results. Wells Fargo lowered its price target to $48.

21 Jul 2026, 23:01 UTC

Social Media

Event

News

Celldex Therapeutics shares fell in after-market hours following disappointing Phase 2 trial results for barzolvolimab, which failed to meet primary and secondary endpoints.

Peer Comparison

Price change

Celldex Therapeutics Inc Forecast

Price Target

By TipRanks

55.51% upside

12 Months Forecast

Average 55.08 USD 55.51%

High 100 USD

Low 34 USD

Based on 14 Wall Street analysts offering 12 month price targets forCelldex Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to Celldex Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

138 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.